Differential effect of dopamine catabolism and uptake inhibition on dopamine-induced calcium dysregulation and viability loss

Free Radical Biology and Medicine

Volumn 27, Issue 11-12, 1999, Pages 1393-1404

  Cantuti Castelvetri, Ippolita ^a   Joseph, James A ^a  

^a Laboratory of Neuroscience   (United States)

Author keywords

Calcium homeostasis; Caspase 3; Cell viability; Dopamine receptor antagonists; Dopamine toxicity; Free radicals; Pargyl MAO inhibitors; Permeability transition pores

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLORGYLINE; CYCLOSPORIN A; DOPAMINE; DOPAMINE TRANSPORTER; FREE RADICAL; MONOAMINE OXIDASE INHIBITOR; NOMIFENSINE; PARGYLINE; REACTIVE OXYGEN METABOLITE; SELEGILINE; SPIPERONE;

ARTICLE; CALCIUM HOMEOSTASIS; CELL VIABILITY; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE UPTAKE; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; OXIDATIVE STRESS; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL;

ANIMALS; CALCIUM; CASPASE 3; CASPASES; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; FLUORESCENT DYES; FREE RADICALS; HOMEOSTASIS; KINETICS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NOMIFENSINE; PARGYLINE; PC12 CELLS; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, DOPAMINE D2; SPIPERONE;

EID: 0033462188     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00188-4     Document Type: Article

References (62)

1. Ambani L.M., Van Woert M.H. Brain peroxidase and catalase in Parkinson disease. Arch. Neurol. 32:1975;114-118.
2. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA. 90:1993;7915-7922.
3. Harman D. Free-radical theory of aging. Increasing the functional life span. Ann. N.Y. Acad. Sci. 717:1994;1-15.
4. Joseph J.A., Denisova N., Villalobos-Molina R., Erat S., Strain J. Oxidative stress and age-related neuronal deficits. Mol. Chem. Neuropath. 28:1996;35-40.
5. Dubey A., Forster M.J., Sohal R.S. Effect of the spin-trapping compound n-tert-butyl- phenylnitrone on protein oxidation and life span. Arch. Biochem. Biophys. 324:1995;249-254.
6. Wagner B.A., Buettner G.R., Burns P. Vitamin E slows the rate of free radical-mediated lipid peroxidation in cells. Arch. Biochem. Biophys. 334:1996;261-267.
7. Shigenaga M.K., Ames B.N. Assays for 8-hydroxy-2′-deoxyguanosine a biomarker of in vivo oxidative DNA damage . Free Radic. Biol. Med. 10:1991;211-216.
8. Orrenius S., McConkey D.S., Nicotera P. Role of calcium in toxic and programmed cell death. Adv. Exp. Med. Biol. 283:1991;419-425.
9. Joseph J.A., Strain J.G., Jimenez N.D., Fisher D. Oxidant injury in PC12 cells - a possible model of calcium "dysregulation" in aging. I. Selectivity of protection against oxidative stress. J. Neurochem. 47:1997;1252-1258.
10. Jenner P., Shapira A.H.V., Mardsen C.D. New insights into the cause of Parkinson's disease. Neurology. 42:1992;2241-2250.
11. De Erasquin G.A., Costa E., Hanbauer I. Calcium homeostasis, free radical formation, and trophic factor dependence mechanisms in Parkinson's disease. Pharm. Rev. 46:1994;467-482.
12. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease. Evidence supporting it. Ann. Neurol. 32:1992;804-812.
13. Sofic E., Riederes P., Heinsen H., Beckman H., Reynolds G.P., Hebenstreit G., Youdim M.B.H. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Trans. 74:1988;199-205.
14. Mytilineou C., Han S.K., Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J. Neurochem. 61:1993;1470-1478.
15. Wang R.-G., Zhu X.-Z. Toxicity of dopamine to mouse neuroblastoma × rat glioma hybrid (NG108) cells in vitro. Acta Pharmacol. Sinica. 16:1995;294-296.
16. Alexander T., Sortwell C.E., Sladek C.D., Roth R.H., Steece-Collier K. Comparison of neurotoxicity following repeated administration of L-DOPA, D-DOPA, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. Cell Transplant. 61:1997;309-315.
17. Filloux F., Townsend J.J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 119:1993;79-88.
18. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl Acad. Sci. USA. 93:1996;1956-1961.
19. 2 production in the rat striatum following transient middle cerebral artery occlusion. Brain Ras. 764:1997;299-302.
20. Toner C.C., Stamford J.A. Involvement of N-and P-/Q- but not L- or T-type voltage gated calcium channels in ischemia-induced striatal dopamine release in vivo. Brain Res. 748:1997;85-92.
21. Suzuki T., Akaike N., Ueno K., Tanaka Y., Himori N. MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/ reperfusion in mice. Pharmacol. 50:1995;357-362.
22. Matsui Y., Kumagae Y. Monoamine Oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia. Neurosci. Lett. 126:1991;175-178.
23. Buisson A., Callabert J., Mathieu E., Plotkine M., Boulu R.G. Striatal protection by lesioning the substantia nigra of rats subjected to focal ischemia. J. Neurochem. 59:1992;1153-1157.
24. Chiueh C.C., Miyake H., Peng M.-T. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv. Neurol. 60:1993;251-258.
25. Sheehan J.P., Swerdlow R.H., Parker W.D., Miller S.W., Davis R.E., Tuttle J.B. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68:1997;1221-1233.
26. Mouatt-Prigent A., Agid Y., Hirsch E.C. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res. 668:1994;62-70.
27. Lynch D.R., Dawson T.M. Secondary mechanisms in neuronal trauma. Curr. Opin. Neurol. 7:1994;507-509.
28. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
29. Wang, H.; Joseph, J. A. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic. Biol. Med. 27:683-694, 1999.
30. Alagarsamy S., Phillips M., Pappas T., Johnson K.M. Dopamine neurotoxicity in cortical neurons. Drug Alcohol Dep. 48:1997;105-111.
31. Offen D., Ziv I., Sternin H., Melamed E., Hochman A. Prevention of dopamine-induced death by thiol antioxidants possible implications for treatment of Parkinson's disease . Exp. Neurol. 141:1996;32-39.
32. Spencer J.P.E., Jenner A., Butler J., Aruoma O.I., Dexter D.T., Jenner P., Halliwell B. Evaluation of the pro-oxidant and antioxidant action of L-DOPA and dopamine in vitro implications for Parkinson's disease . Free Radic. Res. 24:1996;95-105.
33. Michel P.P., Vyas S., Anglade P., Ruberg M., Agid Y. Morphological and molecular characterization of the response of the differentiated PC12 cells to calcium stress. Eur. J. Neurosci. 6:1994;577-586.
34. Zucker R.S. Exocytosis A molecular and physiological perspective . Neuron. 17:1996;1049-1055.
35. 2+-activated cell volume recovery mechanisms. Ann. Rev. Physiol. 52:1990;27-42.
36. Santella L. The role of calcium in the cell cycle facts and hypotheses . Biochem Biophys. Res. Commun. 244:1998;317-324.
37. Ghosh A., Greenberg M. Calcium signaling in neurons molecular mechanisms and cellular consequences . Science. 268:1995;239-247.
38. 2+ is important for the proteolytic processing and intracellular transport of proinsulin in the pancreatic β-cell. Biochem. J. 323:1997;445-450.
39. Johnson C.M., Hill C.S., Chawla S., Treisman R., Bading H. Calcium controls gene expression via three distinct pathways that can function independently of the Ras/mitogen activated protein kinases (ERKs) signaling cascade. J. Neurosci. 17:1997;6189-6202.
40. Simantov R., Blinder E., Ratovitski T., Tauber M., Gabbay M., Porat S. Dopamine- induced apoptosis in human neuronal cells inhibition by nucleic antisense to the dopamine transporter . Neuroscience. 74:1996;39-50.
41. Mattammal M.B., Haring J.A., Chung H.D., Raghu G., Strong R. An endogenous dopaminergic neurotoxin implications for Parkinson's disease . Neurodegeneration. 4:1995;271-281.
42. Ben-Sachar D., Youdim M.B.H. Selectivity of melanized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J. Neural. Trans. 29:1990;251-258.
43. Poirier J., Thiffault C. Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease? Eur. Neurol. 33:(Suppl. 1):1993;38-43.
44. Tatton W.G., Chalmers-Redman R.M.E. Modulation of gene expression rather than monoamino oxidase inhibition (-)-Deprenyl-related compounds in controlling neurodegeneration . Neurology. 47:(Suppl 3):1996;S171-S183.
45. Hely M.A., Morris J.G.L. Controversies in the treatment of parkinson's disease. Curr. Opin. Neurol. 9:1996;308-313.
46. Masserano J.M., Gong L., Kulaga H., Baker I., Wyatt R.J. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol. Pharm. 50:1996;1309-1315.
47. Youdim M.B.H., Hendelman E., Pollard H.B., Fleming P., McHugh E. Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC12 and chromaffin cells. Neuroscience. 19:1986;1311-1318.
48. Chiueh C.C., Huang S.-J., Murphy D.L. Suppression of hydroxyl radical formation by MAO inhibitors a novel possible mechanism in dopaminergic neurotoxicity . J. Neural. Transm. 41:1994;189-196.
49. Tatton W.G., Ju W.Y.L., Holland D.P., Tai C., Kwan M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63:1994;1572-1575.
50. Carrillo M.C., Kitani K., Kanai S., Sato Y., Miyasaka K., Ivy G.O. (-)Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci. 54:1994;975-981.
51. Glover V., Clow A., Sandler M. Effects of dopaminergic drugs on superoxide dismutase implications for senescence . J. Neural Transm. 40:(Suppl):1993;37-45.
52. Buchholz J., Tsai H., Foucart S., Duckels S.P. Advancing age alters intracellular calcium buffering in rat adrenergic nerves. Neurobiol. Aging. 17:1996;885-892.
53. Michaelis M.L., Bigelow D.J., Schöneich C., Williams T.D., Ramonda L., Yin D., Hümer A.F.R., Yao Y., Gao J., Squier T.C. Decreased plasma membrane calcium transport activity in aging brain. Life Sci. 59:1996;405-412.
54. 2+ homeostasis, cell death, proliferation, and differentiation . Chem.-Biol. Interactions. 77:1991;1-23.
55. Beal M.F. Mitochondria, free radicals, and neurodegeneration. Curr. Opin. Neurobiol. 6:1996;661-666.
56. Mizuno Y., Ikebe S., Hattori N., Nakagawa-Hattori Y., Mochizuki H., Tanaka M., Ozawa T. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochem. Biophys. Acta. 1271:1995;265-274.
57. Glinka Y.Y., Youdim B.H.M. Inhibition of mitochondrial respiration complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292:1995;329-332.
58. Westlund K.N., Krakower T.J., Kwan S.W., Abell C.W. Intracellular distribution of monoamine oxidase a in selected regions of rat and monkey brain and spinal cord. Brain Res. 612:1993;221-230.
59. Hattori A., Yongquan L., Umegaki H., Munoz J., Roth G.S. Intrastriatal Injection of dopamine results in DNA damage and apoptosis in rats. Neuroreport. 9:1998;2569-2572.
60. Yongquan L., Umegaki H., Wang X., Abe R., Roth G.S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 273:1998;3756-3764.
61. Yongquan L., Kokkonen G.C., Wang X., Neve K.A., Roth G.S. D2 Dopamine receptors stimulate mitogenesis through pertussis toxin-sensitive g proteins and Ras-involved ERK and SAP/JNK pathways in rat C6-D2L glioma cells. J. Neurochem. 71:1998;980-990.
62. Green D., Kroemer G., Moq̂uet G. The central executioners of apoptosis caspases or mitochondria? TCB. 8:1998;267-271.